Acute respiratory distress syndrome (ARDS) is characterized by acute hypoxemic respiratory failure from noncardiogenic pulmonary edema. Despite inclusion of pediatric subjects in the initial description of ARDS ([@R1]), neither the 1994 American-European Consensus Conference ([@R2]) nor the 2012 Berlin revised definitions of ARDS ([@R3]) addressed pediatric considerations. To inform study design in children with ARDS, the Pediatric Acute Lung Injury Consensus Conference (PALICC) developed a specific definition for pediatric ARDS (PARDS) in 2015 ([@R4]). Notable differences in the PALICC definition include use of oxygenation index (OI), rather than Pa[o]{.smallcaps}~2~/F[io]{.smallcaps}~2~, for severity stratification; explicit use of alternative stratification using peripheral oxygen saturation (Sp[o]{.smallcaps}~2~)(oxygen saturation index \[OSI\]); and inclusion of unilateral, in addition to bilateral, infiltrates on chest radiograph. Both the Berlin and PALICC definitions highlighted the need to better stratify risk, with PALICC specifically recommending the development of prognostic scores to stratify mortality ([@R4], [@R5]). Appropriate risk stratification would permit prognostic enrichment (restriction of trial eligibility to those at highest risk of poor outcome) for clinical trials ([@R6]), as well as allow testing for heterogeneity of treatment effect ([@R7]).

Recently, the Pediatric ARDS Incidence and Epidemiology (PARDIE) study was completed to assess the utility of the PALICC definition, identifying 708 subjects from 145 PICUs worldwide ([@R8]). PARDIE identified three-fold more cases of PARDS using PALICC criteria, compared with Berlin, with improved mortality discrimination with PALICC severity categories. In a preplanned ancillary study (dubbed Version 1 \[V1\]), additional data were collected to assess predictors of mortality. Herein, we present the development and validation of mortality prediction models in PARDS. We hypothesized that a combination of clinical variables could reliably estimate the probability of PICU mortality.

MATERIALS AND METHODS
=====================

The full Methods are available in the **Data Supplement** (Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>). The study was designed and reported consistent with the recommendations of the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis statement (**Appendix 1**, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>). The Children's Hospital of Los Angeles (CHLA, Los Angeles, CA) was the clinical and data coordinating center. The protocol was first approved by the CHLA Institutional Review Board (IRB). PARDIE sites obtained ethical approval from their local IRB or relied on the central CHLA IRB.

Derivation (PARDIE V1) Cohort
-----------------------------

PARDIE consisted of 708 subjects from 145 PICUs in 27 predominantly high-income countries ([@R8]), prospectively screened over 5 days during 10 nonconsecutive weeks between May 2016 and June 2017, with each site deciding a priori whether to participate in the ancillary studies. V1 included additional data from 100 centers (**Appendix 2**, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>). Patients were eligible for PARDIE if they newly met PALICC PARDS criteria. We collected data for the first 3 days after PARDS diagnosis, including demographics, center characteristics, geoeconomic categorization, oxygenation, ventilatory support, radiographs, severity of illness measured using the Pediatric Index of Mortality (PIM) 3 and Pediatric Risk of Mortality (PRISM) IV scores, and comorbidities. Additional data collected for V1 included daily (calendar day) organ failure (Pediatric Logistic Organ Dysfunction \[PELOD\] 2 score), vasopressor requirement, fluid balance, and use of ancillary therapies.

External Validation Cohort
--------------------------

We externally validated the predictive models using a prospective cohort of intubated children meeting Berlin ARDS criteria from the PICU of the Children's Hospital of Philadelphia (CHOP), a 60-bed PICU in a quaternary North American children's hospital, between July 2011 and June 2018. As CHOP was a participant in PARDIE, overlapping subjects were excluded.

Definitions and Outcomes
------------------------

The primary outcome was PICU mortality. Secondary outcomes include duration of ventilation in survivors and ventilator-free days (VFDs) at 28 days. Oxygenation was measured using Pa[o]{.smallcaps}~2~/F[io]{.smallcaps}~2~ and Sp[o]{.smallcaps}~2~/F[io]{.smallcaps}~2~ in all subjects, and OI and OSI in intubated subjects ([@R9], [@R10]). For all analyses, noninvasive measures were converted to invasive equivalents using published equations ([@R9]). Vasopressor-inotrope score was dopamine (µg/kg/min) × 1 + dobutamine (µg/kg/min) × 1 + epinephrine (µg/kg/min) × 100 + norepinephrine (µg/kg/min) × 100 + milrinone (µg/kg/min) × 10 ([@R11]). The designation "immunocompromised" required presence of an oncologic diagnosis, immunodeficiency, stem cell or organ transplant, or a rheumatologic or inflammatory condition receiving immunosuppression ([@R12], [@R13]). Countries were grouped by geographical region and economic status using 2016 World Bank classifications ([@R14]). A single cause of death was assigned by site investigators: hypoxemia, refractory shock, multisystem organ failure (MSOF), brain death, other neurologic cause, or other.

Development of a Model for Mortality Prediction
-----------------------------------------------

Our primary aim was to construct a parsimonious model of clinical variables on day of PARDS onset (day 0) associated with PICU mortality for use in risk prediction. We did this in two steps: penalized regression followed by variable reduction using the Bayesian information criterion (BIC), detailed in the Data Supplement (Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>). Internal validation was evaluated by 10-fold cross-validation and assessment of model performance in prespecified subgroups. Calibration and fit were assessed using the calibration belt ([@R15]). Discrimination for PICU mortality was assessed by calculating area under the receiver operating characteristic (AUROC) curve.

The primary model was developed using the entire V1 cohort, which included intubated and noninvasively ventilated subjects with PARDS, and all-cause mortality. Three subgroup models were built. First, as subjects dying of a neurologic etiology may have different predictors of mortality than those dying of shock, MSOF, or hypoxemia ([@R16]), we repeated the analysis excluding those who died primarily due to a neurologic cause. Second, we repeated the analysis in patients invasively ventilated within 6 hours of PARDS diagnosis. Third, we repeated the analysis in invasively ventilated subjects excluding those who died from a neurologic cause.

External Validation of the Model
--------------------------------

Models were validated using a cohort of children with Berlin ARDS from CHOP. As all CHOP subjects were intubated, we only assessed models for invasively ventilated subjects. Calibration, fit, and discrimination were reported. Since the model was derived from a multicenter cohort, we reasoned that if calibration was poor, the model would be revised in this cohort by reestimation of the coefficients and intercept ([@R17]).

Utility of the Mortality Model to Stratify Ventilator-Free Days
---------------------------------------------------------------

We assessed whether models developed for mortality were calibrated for VFDs in both derivation and validation cohorts. Subjects were split into quartiles of predicted mortality for each of the models. For each quartile, VFDs were modeled as a competing risk, treating discontinuation of ventilation as the primary outcome, and death as a competing event. Outcomes were censored after 28 days, making this equivalent to VFDs at 28 days ([@R18]). Models were constructed for all patients (invasive and noninvasive VFDs) and for intubated patients (invasive VFDs) in the derivation cohort and limited to invasive VFDs for the validation cohort. Noninvasive ventilation was defined as oro-nasal mask continuous positive airway pressure or bilevel positive airway pressure. High-flow oxygen was not counted as noninvasive support.

Development of a Model for Identifying Predictors of Ventilator Duration
------------------------------------------------------------------------

As mortality in PARDS is low, length of ventilation in survivors is an important contributor to VFDs. Therefore, we separately constructed models to identify predictors of total (invasive and noninvasive) and invasive ventilator duration in survivors. We modeled ventilator duration as time to event analyses using Cox regression with clustering by site, censored at 28 days, with variable selection based on BIC optimization, similar to the mortality models.

RESULTS
=======

Description of the V1 Cohort
----------------------------

Description of the V1 cohort (*n* = 624, 108 deaths) stratified by PICU survival status is presented in ****Table [1](#T1){ref-type="table"}****, and more completely in **Supplementary Table 1** (Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>). Nonsurvivors had greater severity of illness scores, more comorbidities, and higher vasopressor scores and fluid balance on the day of PARDS diagnosis (day 0). Nonsurvivors were more likely to have worse oxygenation, irrespective of whether invasively ventilated or not. Finally, nonsurvivors were more likely to come from World Bank-designated middle-income countries. Of the 108 nonsurvivors, 28 (26%) had a primary neurologic etiology as a cause of death.

###### 

Description of the Pediatric Acute Respiratory Distress syndrome Incidence and Epidemiology Version 1 Cohort Stratified by Mortality
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Predictive Models for PICU Mortality from the V1 Cohort
-------------------------------------------------------

****Table [2](#T2){ref-type="table"}**** shows the final model for PICU mortality in the entire cohort. PELOD 2 on day of PARDS diagnosis (day 0), vasopressor score and fluid balance (mL/kg) on day 0 of PARDS, immunocompromised status, and Pa[o]{.smallcaps}~2~/F[io]{.smallcaps}~2~ 6 hours after PARDS diagnosis were included. Neither noninvasive ventilation nor presence of unilateral infiltrates were retained as predictors. The model demonstrated good discrimination (AUROC, 0.82; 95% CI, 0.78--0.87), calibration, and fit (****Table [3](#T3){ref-type="table"}**** and **Fig. [1](#F1){ref-type="fig"}*A***). Ten-fold cross-validation (Table [3](#T3){ref-type="table"}) and testing in prespecified subgroups (**Supplementary Table 2**, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>) suggested good internal validity (all AUROC ≥ 0.80).

###### 

Final Predictive Model for PICU Mortality in the Entire Pediatric Acute Respiratory Distress syndrome Incidence and Epidemiology Version 1 Cohort
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###### 

Predictive Utility, Internal Validation, and Fit of Models
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![Calibration belts for the separate models predicting PICU mortality in the Pediatric Acute Respiratory Distress syndrome Incidence and Epidemiology Version 1 (V1) cohort. The calibration belt examines the relationship between estimated probabilities and observed mortality rates, with associated 80% (*light gray*) and 95% (*dark gray*) CIs. Perfect calibration lies along the center (*dashed*) line. The calibration belt is paired to a statistic that tested deviation from the center line, similar to the Hosmer-Lemeshow test. All four models developed in the V1 cohort demonstrate good calibration (as indicated by *p* \> 0.05 in all models).](ccm-48-e514-g004){#F1}

Separate models (**Supplementary Table 3**, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>) were constructed for the cohort excluding those who died of neurologic causes, for those invasively ventilated 6 hours after PARDS diagnosis, and for those invasively ventilated excluding neurologic deaths. Most of the same variables were retained as predictors in all three subgroup models, with the addition of coming from a middle-income country for the cohort excluding neurologic deaths, the substitution of OI (for Pa[o]{.smallcaps}~2~/F[io]{.smallcaps}~2~) in the invasively ventilated models, and the removal of day 0 fluid balance in the invasively ventilated models. Retention of OI, rather than Pa[o]{.smallcaps}~2~/F[io]{.smallcaps}~2~, resulted in lower BIC in models for intubated subjects. All models (Table [3](#T3){ref-type="table"}) demonstrated good discrimination (AUROC ≥ 0.84) with retention of this property after cross-validation (cross-validated AUROC ≥ 0.83). All models demonstrated good fit (**Fig. [1](#F1){ref-type="fig"}**). The models for the intubated cohort had higher AUROC than the severity of illness scores PIM 3, PRISM IV, and PELOD 2, as well as a published ([@R19]) simplified prediction model (all *p* \< 0.05 when comparing AUROC; ****Table [4](#T4){ref-type="table"}****).

###### 

Performance (Area Under the Receiver Operating Characteristic Curve and 95% CI) of the Mortality Prediction Model Relative to Other Severity of Illness Scores and a Published Model for Predicting Pediatric Acute Respiratory Distress Syndrome Mortality
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Performance of Models in the CHOP Validation Cohort
---------------------------------------------------

Comparison of the PARDIE V1 and the CHOP cohorts are provided in **Supplementary Table 4** (Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>). By design, the CHOP cohort excluded subjects requiring chronic ventilation at baseline and with unrepaired congenital heart disease, and required subjects to be intubated with bilateral infiltrates. Mortality was similar for both the V1 (17%) and CHOP (18%) cohorts.

Both predictive models (intubated subjects, including and excluding neurologic deaths) had good discrimination (both AUROC ≥ 0.85; Table [4](#T4){ref-type="table"}) but poor calibration (**Supplementary Fig. 1**, ***A*** and ***B***, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>), with overestimation of mortality when applied without modification to the CHOP cohort. We reasoned that since CHOP represents a tertiary-care center in a developed country, one could reasonably expect differences in both baseline mortality (intercept) as well as the effect of the variables on mortality (slope). Thus, both models were revised in the CHOP dataset using the same variables (**Supplementary Table 5**, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>). The revised models retained good discrimination (both AUROC ≥ 0.85), with the revised model for the entire intubated cohort continuing to demonstrate poor fit (**Supplementary Fig. 1*C***, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>). The revised model excluding neurologic deaths demonstrated improved fit (**Supplementary Fig. 1*D***, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>).

Utility of Mortality Prediction Models for Stratification of VFDs
-----------------------------------------------------------------

As VFDs are commonly used as an outcome in PARDS, we assessed whether the four models developed for PICU mortality appropriately stratified VFDs (**Supplementary Fig. 2**, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>). For models developed in the whole V1 cohort (Supplementary Fig. 2*A*, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>) and the V1 cohort excluding neurologic deaths (Supplementary Fig. 2*B*, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>), we assessed the relationship between quartiles of predicted mortality and probability of discontinuing total (invasive and noninvasive) ventilation, as not all subjects were intubated. For the models restricted to intubated PARDS (Supplementary Fig. 2*C*, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>) and intubated PARDS excluding neurologic deaths (Supplementary Fig. 2*D*, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>), we assessed the relationship between quartiles of predicted mortality and probability of extubation. For all four models, probability of successful discontinuation of ventilation was appropriately stratified by quartile, with lower probability of discontinuing ventilation (i.e., fewer VFDs) with higher predicted mortality. When we performed a parallel analysis in the CHOP validation cohort of intubated PARDS, both original (**Supplementary Fig. 3**, ***A*** and ***B***, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>) and revised models (**Supplementary Fig. 3**, ***C*** and ***D***, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>) appropriately stratified VFDs.

Models for Ventilator Duration in Survivors
-------------------------------------------

PARDIE V1 survivors (**Supplementary Table 6**, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>) experienced a median of 7.4 days (interquartile range, 4.1--13.0 d) of total (invasive and noninvasive) ventilation, and 6.1 days (interquartile range, 3.1--11.3 d) of invasive ventilation. Factors associated with lower probability of discontinuing total ventilation included higher PELOD 2 and vasopressor score on day of PARDS diagnosis, presence of any comorbidity, and more PICU days before meeting PARDS criteria. Factors associated with lower probability of extubation included vasopressor score on day of PARDS diagnosis, OI at 6 hours after PARDS onset, PICU days before meeting PARDS criteria, and having greater than or equal to 15 PICU beds (**Supplementary Table 7**, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>).

DISCUSSION
==========

PARDS is a heterogeneous syndrome, and severity adjustment tools are important for clinical trial design. To date, there has not been a readily available and generalizable model for risk stratification in PARDS, with mortality prediction limited to models developed in few centers ([@R13], [@R19], [@R20]). We developed models for prediction of PICU mortality using variables from the first day of PARDS from a multinational cohort (Table [2](#T2){ref-type="table"}; and Appendix 2, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>). The models use readily available clinical data, demonstrate good discrimination and calibration, perform well in subgroups, and outperform published severity of illness scores. Several of the variables in the mortality models are implicated in duration of ventilation, and the mortality prediction model appropriately stratifies VFDs. We externally validated models developed for intubated subjects, thus directly addressing the generalizability concerns of previous models.

A variable selection strategy balancing parsimony and predictive utility protected against over-fitting and increased utility of the models by reducing the number of variables. All of the retained variables have been implicated in PARDS mortality, including immunocompromised status ([@R13], [@R19]) and organ failure ([@R13], [@R20]). Being from a middle-income country was retained as a predictor in the model excluding subjects dying from neurologic causes. This requires further investigation to identify potential causes of an apparent association between geoeconomic status and mortality. Notably, this is consistent with the lower survival in adults with ARDS from middle-income countries seen in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure ([@R14]). However, it is important to note that only 13% of subjects in PARDIE V1 were from a middle-income country, with complete absence of African representation, limiting any definitive inferences regarding this association.

As in previous studies ([@R16]), hypoxemia was responsible for a minority of deaths, whereas MSOF and neurologic etiologies were responsible for a larger fraction. In both adult ARDS ([@R21], [@R22]) and PARDS ([@R8], [@R16], [@R20]), neurologic etiologies of death are common. Many of these subjects would be excluded from clinical trials due to their neurologic prognosis ([@R22]), yet are commonly retained in observational studies, contributing to lower than expected mortality rates in trials. The separate model for intubated patients excluding subjects dying of neurologic causes thus may have greatest utility in clinical trials, as this most closely resembles trial populations, with the caveat that neurologic status may be difficult to assess at PARDS onset.

VFDs are commonly used in trials of adult ARDS and in PARDS. As mortality in pediatrics is lower than adults ([@R12], [@R23]), ventilator duration in survivors is an important contributor to calculating VFDs. For both models predicting ventilator duration (total and invasive ventilation), variables with the highest importance were also present in the models predicting mortality. Overall, this supports the utility of the mortality prediction models for predicting other clinically relevant outcomes, such as VFDs, which we demonstrated in both the derivation (Supplementary Fig. 2, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>) and validation (Supplementary Fig. 3, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>) cohorts.

Models for intubated subjects were validated in a prospective cohort from CHOP, a large, tertiary-care North American PICU restricted to invasively ventilated subjects with Berlin ARDS, requiring arterial access and bilateral infiltrates. This cohort had higher vasopressor scores, better oxygenation, and more neurologic deaths than the V1 cohort. When comparing the coefficients between the original derivation (Supplementary Table 3, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>) and the revised (Supplementary Table 5, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>) models, several coefficients demonstrated downward attenuation. For example, in the revised model for the entire intubated CHOP cohort, the coefficient for PELOD 2 was 27% lower, the coefficient for immunocompromised status was 38% lower, and the coefficient for OI was 34% lower. These results suggest that the impact of these variables on mortality is lower in the CHOP cohort, and that fit remains poor because even this revised model does not capture the best predictors of mortality in this specific PICU, despite identical discrimination (Table [4](#T4){ref-type="table"}). Notwithstanding this limitation, the model and variables elected may retain some utility, as both original and revised models appropriately stratify VFDs in the CHOP cohort (Supplementary Fig. 3, Supplemental Digital Content 1, <http://links.lww.com/CCM/F458>).

The greater percentage of neurologic deaths at CHOP may also contribute to the poor fit, despite revision, of the model developed for all intubated subjects. Notably, the model excluding neurologic deaths demonstrated perfect fit after revision, confirming that cause of death may be impacting the utility of the models. This suggests that, in addition to recalibration or revision, models both including and excluding neurologic deaths need to be tested in a given setting.

We believe that the models offered here are a first step toward improved outcome prediction in PARDS, confirming that a few readily available clinical variables can stratify mortality risk, which will assist with prognostic enrichment for trials ([@R6]), and for identifying heterogeneity of treatment effect post hoc ([@R7]). We expect further refinement and encourage additional external validation of these models in other PARDS cohorts, particularly in traditionally underrepresented settings.

Strengths of our study include model development in a large, modern, multinational cohort; good internal validation and calibration; and external validation in a separate, large cohort. Our conclusions are based on observations in greater than 1,200 children with PARDS. However, there are limitations to our study. First, variables such as PELOD 2 score, fluid balance, and vasopressor score were collected for the calendar day of PARDS diagnosis, with no adjustment for whether that encompassed 24 hours or a shorter interval. Second, our primary outcome was PICU mortality, rather than hospital mortality, as we reasoned that factors associated with acute PARDS are more likely to affect short-term outcomes, while underlying comorbidities may be more responsible for longer-term outcomes. Third, external validation was only performed in a single-center cohort with different eligibility criteria. Other external validation cohorts which were considered were missing necessary data elements, precluding testing of these models. Accordingly, we believe future PARDS studies should routinely collect these data elements. Fourth, as our focus was on accurate risk stratification for clinical trials, we only tested variables on day 0 of PARDS, which is within the timeframe for recruitment for most studies. The utility of longitudinal models is unknown, but it is possible that these would be an improvement over a static day 0 model. Finally, while an improvement upon existing models, performance of the models for mortality prediction are inadequate to support clinical utility for bedside prognostication at this time.

CONCLUSIONS
===========

We developed and validated predictive models for PICU mortality in PARDS with good performance, which can assist with risk stratification for clinical trials. Development of models excluding neurologic deaths may be of particular utility, as they commonly exclude such subjects. Several variables associated with mortality are also implicated in duration of ventilation, and we confirmed utility of models for stratifying VFDs. All variables represent routinely available clinical data from the first day of PARDS, and should consistently be collected in future investigations. At this time, model performance is inadequate to support clinical utility at bedside. Studies are warranted to further validate and update these models in other PARDS cohorts, and to test whether operationalized use of the model is feasible in a trial.
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